Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Clinical trial NCT07046221 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07046221
- Sponsor
- Fujian Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-01
- Primary completion
- 2027-08-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.